Clinical Investigation of a Novel Spectacle Lens on Slowing Down Juvenile Myopia Progression
Essilor International
35 participants
Jun 26, 2025
INTERVENTIONAL
Conditions
Summary
The goal of this exploratory clinical trial is to evaluate the efficacy and safety of a test spectacle lens (standard single vision lens (SVL) during first year, and standard myopia control lens (MCL) in second year), designed with passive red-light emission, for the control of myopia progression in myopic children age 6 to 11 years old, both male and female, with no systemic or ocular anomalies. The main question it aims to answer is: Does the test spectacle lens designed with passive red-light emission provide significant myopia control effect to children? Researchers will compare the standard SVL designed with passive red-light emission to SVL (first year) and MCL designed with passive red-light emission to MCL (second year) to see if the test spectacle lens work to slow down myopia progression. Participants will: * Wear the study spectacles * Visit Essilor R\&D Centre for follow-up sessions
Eligibility
Inclusion Criteria7
- Children equal to or greater than 6 years old and less than 11 years at the time of signing informed consent.
- Corrected spherical equivalent refraction (SER) between -0.75 D and -5.00 D with astigmatism not more than 2.50 D.
- Difference in SER (Anisometropia) between two eyes should not exceed 1.00 D.
- Best corrected visual acuity better than or equal to +0.10 log MAR (20/25 or better with Snellen).
- Be in good general health, based on his/her and parent's/guardian's knowledge.
- Agree to wear spectacles for >12 hours/day and at least 6 days/week.
- Willingness and ability to participate in investigation for 2 years and attend scheduled visits.
Exclusion Criteria6
- Any ocular or systemic pathologies known to affect refractive status (e.g. keratoconus, diabetes, Down's syndrome etc.)
- Any binocular vision anomalies
- Amblyopia
- Use of prior myopia control treatment like specialized myopia control spectacles and contact lenses at least in the previous one month.
- Current use of ocular or systemic medications which, in the investigator's opinion, may significantly affect pupil size, accommodation or refractive state.
- Participation in any clinical investigation within 30 days of the baseline visit.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Dispensed to one eye in Year 1
Dispensed to the contralateral eye in Year 1.
Dispensed to one eye in Year 2 (if used SVL with passive red-light emission in Year 1).
Dispensed to the contralateral eye in Year 2 (if used SVL in Year 1).
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06850168